The data reported below speak for themselves and make it clear, IMO, that TMC435 is the best HCV protease inhibitor on the market or in late-stage development.
Pretty hard to disagree with you on this. I only wish TMC435 were still unpartnered, but presumably Medivir would be at a higher valuation anyways if TMC435 were still unpartnered (on the expectation of a lucrative deal); I think JNJ ought to go ahead and consider acquiring Medivir outright, at this valuation.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.